secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-024000
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Q1 net loss $4.6M; pauses REM-001 to save $3M, continues VAL-083 trial
------------------------------------------------------------------------------

- Net loss of $4.6M ($0.07/share) for quarter ended Sep 30, 2022, vs $6.0M ($0.25) a year ago.
- Cash and equivalents $7.1M at Sep 30, down from $11.8M at Jun 30; net $1.9M from Lincoln Park equity line.
- Paused REM-001 CMBC program to conserve cash; expects to save ~$3.0M through 2023.
- VAL-083 GBM AGILE registrational study ongoing; top-line data expected around end of 2023.
- Entered $20M purchase agreement with Lincoln Park Capital; $1.9M received as of Nov 8.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017022024000/0000950170-22-024000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017022024000/ktra-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer